Latest Articles
Medicus Pharma Submits Ind Application for PRECISION-E2 Phase 2A Study of Teverelix in Endometriosis in United Arab Emirates - marketscreener.com
Medicus Pharma Submits Ind Application for PRECISION-E2 Phase 2A Study of Teverelix in Endometriosis in United Arab Emirates marketscreener.com
Published: June 11, 2026, 1:52 p.m.
Medicus Pharma to Present Phase 1 Teverelix Data at Endocrinology Meeting - MyChesCo
Medicus Pharma to Present Phase 1 Teverelix Data at Endocrinology Meeting MyChesCo
Published: April 17, 2026, 6 a.m.
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy - TipRanks
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy TipRanks
Published: April 15, 2026, 1:38 p.m.
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - The Manila Times
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression The Manila Times
Published: April 15, 2026, 11:45 a.m.
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - GlobeNewswire
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression GlobeNewswire
Published: April 15, 2026, 11:30 a.m.
Link copied to clipboard!